-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JvtN0NlPYfYpFli4OwzAbB4mAKihl6bsLTsyosWoMaRQt+LGVgzs65C+24YwYK8L h3TiMnTDf8cYJ6mhhBCHcg== 0000950130-97-005043.txt : 19971117 0000950130-97-005043.hdr.sgml : 19971117 ACCESSION NUMBER: 0000950130-97-005043 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19971110 ITEM INFORMATION: FILED AS OF DATE: 19971114 SROS: AMEX FILER: COMPANY DATA: COMPANY CONFORMED NAME: ROBERTS PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0000853022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222429994 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 001-10432 FILM NUMBER: 97719127 BUSINESS ADDRESS: STREET 1: 4 INDUSTRIAL WAY WEST CITY: EATONTOWN STATE: NJ ZIP: 07755 BUSINESS PHONE: 7323891182 MAIL ADDRESS: STREET 1: 4 INDUSTRIAL WAY WEST CITY: EATONTOWN STATE: NJ ZIP: 07755 8-K 1 FORM 8-K FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of l~34 Date of Report (Date of earliest event reported) November 10, 1997 ROBERTS PHARMACEUTICAL CORPORATION - -------------------------------------------------------------------------------- (exact name of registrant as specified in its charter) NEW JERSEY 1-1-432 22-2429994 - ----------------- ------------- ---------------- (State or other (Commission (IRS Employer jurisdiction of File Number) Identification incorporation) Number) Meridian Center II 4 Industrial Way West Eatontown, New Jersey 07724 - -------------------------------------------------------------------------------- (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: 908-389-1182 Meridian Center II 4 Industrial Way West Eatontown, New Jersey 07724 - -------------------------------------------------------------------------------- (Former name or former address, if changed from last report) -2- Item 5. Other Events ------------ Roberts Pharmaceutical Corporation announced today the successful completion of a Phase la study of LY315535, a gastrointestinal (GI) compound acquired from Lilly. The compound is being developed by Roberts for the treatment of Functional Bowel Disorders. The Phase la single rising dose study in human volunteers was conducted for Roberts by PPD Pharmaco (Austin, Texas). The objectives of the placebo- controlled study were to 1) show safety across a range of doses and 2) establish a maximum tolerated dose. The study demonstrated a favorable safety profile with LY315535 being well-tolerated across a broad range of doses. The next stage of Phase I testing in humans is scheduled to commence shortly. LY315535 is a novel compound which acts as both a muscarinic receptor antagonist and as a serotonin (5-HT) receptor agonist with a high degree of selectivity for the 5-HTlA receptor subtype. LY315535 is a potentially potent, orally administrated drug which is much needed in a large and generally unsatisfied GI market. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ROBERTS PHARMACEUTICAL CORPORATION ---------------------------------- (Registrant) Date: November 14, 1997 By: /s/ Anthony A. Rascio ------------------------------- Anthony A. Rascio Vice President -----END PRIVACY-ENHANCED MESSAGE-----